P657 Health-related quality of life of patients with inflammatory bowel disease is increased during treatment with biological therapy
A. S. Holdam, P. Bager*, J. F. Dahlerup
Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus, Denmark
Inflammatory bowel diseases (IBDs) have a considerable effect on the patients’ health-related quality of life (HRQoL). We aimed to investigate the effect of biological therapy on the HRQoL for patients with IBD followed in an outpatient clinical setting, to compare the levels of HRQoL with IBD patients without disease activity.
Observational and retrospective study in patients treated with biological therapy. The Short Health Scale (SHS) questionnaire on subjective health consisting of 4 items (bowel symptoms, interference in daily life, worry, and general well-being) was completed and registered in each patient’s medical journal. Data on HRQoL were collected at the beginning of treatment and every 3 months thereafter. The biologically treated group was compared with a control group of patients with IBD without disease activity.
We identified 114 patients who were either naïve to biological therapy or had had a pause in treatment of more than 3 months and who began a new round of treatment. After 3 months of therapy, significant improvements in HRQoL compared with baseline were observed for every item on the SHS (p-value < 0.01). Sub-group analysis showed a poorer performance of HRQoL in women, in patients with Crohn’s disease, and in smokers. The median score regarding bowel symptoms and interference in daily life was similar to the control group after 6 months of treatment.
Treatment with biological therapy leads to a statistically and clinically significant improvement in HRQoL in all parameters. After 6 months of treatment, bowel symptoms and interference in daily life were similar to those inpatients without disease activity.